BPC-157 in 2026: what changed, what hasn't, and what to expect
FDA removed BPC-157 from Category 2, FDA's advisory committee voted, and FDA's final decision is pending. Here is where BPC-157 sits as of September 2026.
TL;DR
- Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
- In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn.
- In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory. As of September 2026, FDA has not made a final decision.
What it is
The FDA's compounding framework sorts substances proposed for use in 503A compounding into categories. Category 1 substances are those FDA is still evaluating. FDA's policy of not taking action against compounding with a substance not yet on the 503A bulks list applies only to Category 1 substances, when other conditions are met. Category 2 substances are those FDA says raise significant safety risks. BPC-157 — a synthetic peptide derived from a fragment of human gastric juice — was placed in Category 2 in 2023. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In July 2026, the Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the Section 503A bulk drug substances list.
How it works
Adding a substance to the Section 503A bulk drug substances list follows a defined sequence. Step one: HHS or FDA issues a public statement of intent. Step two: FDA opens a formal review and a public comment period through the Federal Register. Step three: the Pharmacy Compounding Advisory Committee (PCAC) typically meets to review evidence. Step four: FDA issues a final Federal Register notice formally deciding whether to add the substance to the list. FDA's interim categories work differently: FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. The July 23–24, 2026 PCAC vote was the committee review. As of September 2026, FDA has not taken the final step.
Who asks about it
People come to this question after seeing headlines that BPC-157 is "legal again" or "back on the market." The clean way to read those headlines as of September 2026 is: FDA removed BPC-157 from Category 2 in April 2026, FDA's advisory committee voted to recommend BPC-157 for the 503A bulks list, and FDA has not yet made a final decision.
What the research says
The Federal Register is the official daily publication of the U.S. government and is the authoritative source for FDA rule changes (Federal Register). The FDA also maintains a public list of bulk drug substance nominations under 503A, with status notes for each substance (FDA 503A Bulks List). Patients and physicians watching this space should bookmark both — they update faster than secondary commentary.
What to know before considering it
Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Research-use-only suppliers operate outside the licensed channel and have been associated with documented purity, sterility, and labeling issues. Halftime Health does not source through those channels. When FDA makes a final decision, we will describe it plainly in this blog.
The Halftime POV
The honest version of the BPC-157 story in 2026 is "further along, not finished." FDA removed BPC-157 from Category 2, the advisory committee voted, and FDA has not yet made its final decision. We report the status as it actually is, not as it might be by the end of the year.
Related reading:
- BPC-157: what this body protection compound is
- BPC-157 and the Category 2 question
- Category 1 vs Category 2 peptides: the access framework
FAQ
Q: Is BPC-157 legal to buy in 2026? A: BPC-157 is not FDA-approved. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Q: Did BPC-157 get reclassified? A: FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Q: Where can I get BPC-157? A: Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Research-use-only sources are not legal channels for human use and carry quality risks documented in the literature.
Q: When will the change happen, if it happens? A: A typical Federal Register process takes several months from intent to final rule. PCAC meeting timing and public comment windows shape the schedule.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Federal Register — official daily publication of U.S. government rules and notices
- Bulk Drug Substances Nominations Received for Use in Compounding Under Section 503A — FDA, 2024
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA, 2026
- Bulk-list bound? PCAC backs majority of peptides in two-day public meeting — McDermott Will & Schulte, 2026
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Is BPC-157 legal to buy in 2026?
BPC-157 is not FDA-approved. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Did BPC-157 get reclassified?
FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Where can I get BPC-157?
Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Research-use-only sources are not legal channels for human use and carry quality risks documented in the literature.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.